NBIX Neurocrine Biosciences (NBIX) Q2 FY26 earnings call
Neurocrine Biosciences delivered a record second quarter, driven by strong performance across its diversified commercial portfolio, including INGREZZA, CRENESITY, and the newly acquired VYKAT XR. The company is successfully executing its strategy of commercial growth, pipeline advancement, and disciplined capital deployment, positioning it for long-term value creation. Integration of VYKAT XR is progressing, with expectations for sequential growth exiting 2026, while key Phase III data readouts for osavampator and direclidine are anticipated in 2027.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.